Christchurch biotech firm PharmaZen – better known as Waitaki Biosciences – has found out the hard way what happens when relations with an investor sour.
As reported in The Bottom Line on Dealmakers over the weekend, the USX-list
Subscribe to The Bottom Line to read the full story.